Striving to maintain the Hatch-Waxman balance between innovation and access to affordable prescription drugs, the Massachusetts Supreme Judicial Court closed the door on holding a brand manufacturer responsible for state failure-to-warn claims, due to negligence, stemming from use of a generic product.